Precipio Inc
Company Profile
Business description
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
Contact
4 Science Park
3rd Floor
New HavenCT06511
USAT: +1 203 787-7888
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
71
Stocks News & Analysis
stocks
Do AI labs like Anthropic and OpenAI have economic moats?
stocks
12 picks for an income portfolio - Q3 2026 update
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.00 | 59.30 | 0.67% |
| CAC 40 | 7,832.88 | 29.55 | 0.38% |
| DAX 40 | 25,277.68 | 190.41 | 0.76% |
| Dow JONES (US) | 51,896.13 | 241.18 | 0.47% |
| FTSE 100 | 10,656.28 | 104.23 | 0.99% |
| HKSE | 24,271.20 | 59.85 | 0.25% |
| NASDAQ | 27,306.99 | 59.18 | -0.22% |
| Nikkei 225 | 69,030.92 | 11.19 | -0.02% |
| NZX 50 Index | 13,827.62 | 78.27 | 0.57% |
| S&P 500 | 7,815.22 | 3.68 | 0.05% |
| S&P/ASX 200 | 8,783.20 | 66.60 | 0.76% |
| SSE Composite Index | 3,797.24 | 16.55 | -0.43% |